Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · IEX Real-Time Price · USD
10.50
-0.51 (-4.63%)
Jul 22, 2024, 10:17 AM EDT - Market open
Atara Biotherapeutics Employees
Atara Biotherapeutics had 225 employees as of December 31, 2023. The number of employees decreased by 109 or -32.63% compared to the previous year.
Employees
225
Change (1Y)
-109
Growth (1Y)
-32.63%
Revenue / Employee
$154,240
Profits / Employee
-$1,036,031
Market Cap
55.47M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Inotiv | 2,055 |
Allurion Technologies | 504 |
Barinthus Biotherapeutics | 130 |
Turnstone Biologics | 80 |
Aerovate Therapeutics | 51 |
LAVA Therapeutics | 37 |
Immix Biopharma | 17 |
Ocuphire Pharma | 14 |
ATRA News
- 5 days ago - Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Business Wire
- 16 days ago - Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum - Business Wire
- 4 weeks ago - Atara Biotherapeutics' Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases - Business Wire
- 5 weeks ago - Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split - Business Wire
- 6 weeks ago - Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 7 weeks ago - Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting - Business Wire
- 2 months ago - Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA - Business Wire